PDCD6IP: A Potential Drug Target and Biomarker (G10015)

Target Name: PDCD6IP

NCBI ID: G10015

PDCD6IP

PDCD6IP: A Potential Drug Target and Biomarker

PDCD6IP (Promyelocytic leukemia Death-Inducing Dose) is a protein that is expressed in various types of leukemia cells, including human leukemia cells. It is a key regulator of the cell cycle and has been implicated in the development and progression of many types of leukemia. PDCD6IP has also been identified as a potential drug target and biomarker for the treatment of leukemia.

The protein PDCD6IP is composed of 110 amino acid residues and has a molecular weight of 11.9 kDa. It is expressed in various tissues and cells, including the brain, spinal cord, and blood cells. It is highly expressed in leukemia cells and has been used as a marker for the diagnosis and prognosis of many types of leukemia.

PDCD6IP has been shown to play a role in the regulation of the cell cycle and in the control of cell survival. It is a key regulator of the G1 phase of the cell cycle and has been shown to promote the G1/S transition. This transition is important for the growth and survival of cancer cells, and is a critical step in the development of leukemia.

PDCD6IP has also been shown to play a role in the regulation of apoptosis (programmed cell death). Apoptosis is a natural process that is involved in the elimination of damaged or dysfunctional cells in the body. PDCD6IP has been shown to promote apoptosis in leukemia cells and has been implicated in the development of leukemia.

PDCD6IP has also been shown to play a role in the regulation of inflammation. Leukemia cells often produce inflammation-promoting molecules, such as interleukin-6 (IL-6), which can contribute to the development and progression of leukemia. PDCD6IP has been shown to regulate the production of IL-6 by leukemia cells and has been shown to have anti-inflammatory effects.

PDCD6IP has also been shown to play a role in the regulation of stem cell biology. Leukemia cells are often resistant to chemotherapy and have a limited ability to undergo apoptosis, which can contribute to their survival. PDCD6IP has been shown to regulate the ability of leukemia cells to undergo apoptosis and to promote the production of stem cells.

PDCD6IP has also been shown to play a role in the regulation of the immune response. Leukemia cells often evade the immune system and can continue to multiply and promote the spread of the disease. PDCD6IP has been shown to regulate the production of immune cells and to enhance the ability of leukemia cells to evade the immune system.

PDCD6IP has also been shown to play a role in the regulation of angiogenesis (the formation of new blood vessels). Leukemia cells often require the formation of new blood vessels to provide oxygen and nutrients and to promote their growth and survival. PDCD6IP has been shown to regulate the formation of new blood vessels in leukemia cells and has been shown to have anti-angiogenic effects.

PDCD6IP has also been shown to play a role in the regulation of the blood-brain barrier. The blood-brain barrier is a barrier that separates the brain from the blood and is designed to protect the brain from harmful substances. PDCD6IP has been shown to regulate the formation of the blood-brain barrier in leukemia cells and has been shown to have neurotoxic effects.

PDCD6IP has also been shown to play a role in the regulation of the metabolism of glucose. Leukemia cells often have altered levels of glucose metabolism, which can contribute to their survival and the development of leukemia. PDCD6IP has been shown to regulate the metabolism of glucose in leukemia cells and has been shown to have anti-diabetic effects.

PDCD6IP has also been shown to play a role in the regulation of the

Protein Name: Programmed Cell Death 6 Interacting Protein

Functions: Multifunctional protein involved in endocytosis, multivesicular body biogenesis, membrane repair, cytokinesis, apoptosis and maintenance of tight junction integrity. Class E VPS protein involved in concentration and sorting of cargo proteins of the multivesicular body (MVB) for incorporation into intralumenal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome. Binds to the phospholipid lysobisphosphatidic acid (LBPA) which is abundant in MVBs internal membranes. The MVB pathway requires the sequential function of ESCRT-O, -I,-II and -III complexes (PubMed:14739459). The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis (PubMed:17853893, PubMed:17556548). Adapter for a subset of ESCRT-III proteins, such as CHMP4, to function at distinct membranes. Required for completion of cytokinesis (PubMed:17853893, PubMed:17556548, PubMed:18641129). May play a role in the regulation of both apoptosis and cell proliferation. Regulates exosome biogenesis in concert with SDC1/4 and SDCBP (PubMed:22660413). By interacting with F-actin, PARD3 and TJP1 secures the proper assembly and positioning of actomyosin-tight junction complex at the apical sides of adjacent epithelial cells that defines a spatial membrane domain essential for the maintenance of epithelial cell polarity and barrier (By similarity)

The "PDCD6IP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDCD6IP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets